- Home
- ASM vs IOVA Comparison
ASM vs IOVA Comparison
Compare ASM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | IOVA |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.7M | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ASM | IOVA |
|---|---|---|
| Price | $9.74 | $2.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $8.18 | ★ $10.45 |
| AVG Volume (30 Days) | 9.3M | ★ 11.5M |
| Earning Date | 03-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 476.57 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | $86,065,000.00 | ★ $250,425,000.00 |
| Revenue This Year | $38.58 | $60.71 |
| Revenue Next Year | $39.81 | $59.35 |
| P/E Ratio | $72.09 | ★ N/A |
| Revenue Growth | 58.42 | ★ 175.62 |
| 52 Week Low | $1.15 | $1.64 |
| 52 Week High | $11.99 | $6.09 |
Technical Indicators
Market Signals| Indicator | ASM | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 51.84 |
| Support Level | $9.26 | $2.48 |
| Resistance Level | $10.92 | $2.68 |
| Average True Range (ATR) | 0.99 | 0.18 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 32.75 | 46.15 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.